Although it is widely known that obesity increases the risk of diabetes and cardiovascular disease, the negative effects on the skeleton are often overlooked. Excess body fat can impede bone metabolism, weaken bone quality, and impede fracture repair. In people with metabolic disorders, fat cells accumulate in the bone marrow, which can interfere with the activity of bone-forming cells and damage the network of blood vessels that support skeletal tissues. These changes increase the risk of fractures and reduce the body’s ability to regenerate bone after injury. Despite these clinical challenges, the biological mechanisms linking metabolic diseases and bone health remain poorly understood.
To explore this link, a research team led by Professor Christa Maes of the Institute of Skeletal Cell Biology and Physiology at the University of Leuven, Belgium, investigated the role of hypoxia-inducible factor (HIF) signaling, a molecular pathway that allows cells to adapt to hypoxic environments while regulating metabolism, angiogenesis, and tissue repair. Using a mouse model of high-fat diet (HFD)-induced obesity, the research team administered FG-4592 (roxadustat), a HIF-prolyl hydroxylase domain enzyme (PHD) inhibitor already approved to treat certain anemias. Feeding mice an HFD to mimic metabolic stress allowed the researchers to examine whether activation of hypoxic signaling could improve both metabolic health and skeletal integrity under obesity-inducing conditions. Their findings were published in Volume 14 of the journal. bone research February 11, 2026.
“We hypothesize that activation of the HIF pathway may be an effective therapeutic strategy to enhance both metabolism and skeletal integrity. Under metabolic stress Professor Maes says:
Experiments revealed significant metabolic benefits in treated animals. Activation of hypoxic signaling pathways significantly reduced weight gain and limited peripheral fat accumulation despite continuous exposure to HFD. Treated mice also showed improved glucose tolerance, indicating better control of blood sugar levels. Researchers found that these metabolic improvements were associated with increased energy expenditure, suggesting that this intervention helps the body burn more energy instead of storing it as fat.
Equally important is the protective effect on bone tissue. Obesity often causes excessive accumulation of fat cells in the bone marrow, disrupting the balance between bone formation and fat storage. In treated mice, activation of HIF signaling prevented abnormal bone marrow fat accumulation while preserving the vascular network within the bones. Maintaining this vascular system is essential as it provides oxygen, nutrients, and molecular signals that support bone maintenance and regeneration.
The researchers also examined fracture healing under metabolic stress. Obesity and impaired glucose metabolism usually slow down bone regeneration and can weaken or even fail repair after injury. However, mice treated with roxadustat showed improved fracture healing compared to untreated obese animals, which showed impaired bone repair, demonstrating that activation of hypoxic signaling can restore bone regenerative capacity.
“Our findings show that using PHD inhibitors activates hypoxic signaling. have double beneficial effects, Improves metabolism and bone health at the same time. ” Professor Maes says:
This study goes beyond experimental results and highlights potential ramifications across multiple research fields. Hypoxia signaling pathways regulate energy metabolism, vascular biology, and tissue regeneration and are relevant for research in diabetes, aging, and regenerative medicine.
In the short term, the findings suggest that treatments that activate hypoxic signaling may help reduce bone complications in obese or prediabetic patients. In the long term, such approaches may contribute to treatments that simultaneously manage metabolic diseases and enhance skeletal resilience. If similar effects are confirmed in humans, future treatments could reduce fracture risk, improve recovery after bone injury, and address metabolic dysfunction with a single integrated strategy.
sauce:
Reference magazines:
Valeteny, R. others. (2026). Pharmacological HIF activation exerts dual beneficial effects on energy metabolism and bone, thereby preventing diet-induced obesity, glucose intolerance, and skeletal dysfunction. Bone research. DOI: 10.1038/s41413-025-00503-3. https://www.nature.com/articles/s41413-025-00503-3
